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To estimate the budget impact of introducing Rosuvastatin into the current Brazilian 
national drug formulary. METHODS: A Monte Carlo simulation was used to analyze 
the costs and consequences of treatment with rosuvastatin and atorvastatin. The 
effectiveness of statins in low-density lipoprotein (LDL) reduction was obtained using 
clinical data from published systematic review. We used the log-normal distribution 
for costs using government prices (in Brazilian reais -BRL). The temporal horizon used 
is 1 year. Using the Healthcare System database we described the evolution of con-
sumption of statins in Brazilian Health System. Univariate and probabilistic sensitivity 
analysis tested model robustness. RESULTS: The Rosuvastatin is cost saving when 
compared to atorvastatin, (BRL$215,46 per patient), having an incremental cost-
effectiveness ratio (ICER) of BRL$116,84. These results are expected, as rosuvastatin 
is cheaper and more efﬁcacious than atorvastatin. For a willingness to pay of 
BRL$30,00/percentual reduction in LDL, rosuvastatin 10 mg should be chosen as      
more cost-effective in 75% of the cases when compared to atorvastatin 20 mg. The   
budget impact analysis showed that introduction Rosuvastatin into formulary drug 
could generate minimum savings of the total budget BRL $10 millions/year (US$4.18 
millions dollars). CONCLUSIONS: The Rosuvastatin is the statin more cost-effective 
than Atorvastatin in treatment of hypercholesterolemia to patients that need high 
reduction in LDL. Their inclusion into Brazilian National Drug Formulary is cost 
saving and is aligned with the health authority strategy of cost containment or reduc-
tion for this class of medicines.
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OBJECTIVES: Type I Gaucher’s disease (GD) and Fabry’s disease (FD) are rare genetic 
disorders which in their severest form cause great disability or may be life threatening. 
Treatment for these conditions includes costly enzyme replacement therapy (ERT) with 
uncertain evidence of effectiveness. With increasing frequency ERT has been ﬁnanced 
with National Health Insurance funds in response to court rulings. This study seeks 
to estimate the economic burden of GD and FD for Colombian society. METHODS: 
We developed a stochastic, discrete event simulation model of the natural history of 
these diseases with and without ERT and their respective direct and indirect costs 
during a 15 year period (2008–2022) for a hypothetic cohort of patients. Model 
parameters were obtained from secondary data from local and international sources, 
expert opinion and administrative cost databases from a national health insurance 
plan. One-way sensitivity analyses included scenarios with different population disease 
prevalence and ERT dosage. RESULTS: In the best scenarios the 15-year total cost of 
the cohort is between USD$319 and 533 million for GD and between US$84 and 92 
million for FD. Costs of ERT represent more than 95% of total cost. For the year 
2008 the annual cost of ERT per patient for either disease was around US$175,000. 
CONCLUSIONS: A decision to ﬁnance ERT for these diseases with public funds 
would require an amount of resources that exceeds by far the available budget and 
would imply not providing treatment for other diseases. Given that a recent Consti-
tutional Court ruling mandates reforms to the Colombian beneﬁts packages and their 
rationing mechanisms, our results highlight the importance of economic evaluation 
for sound decision making. Development and enforcement of national treatment 
guidelines for rare diseases is needed. Financing policies should be coherent with the 
objective of providing comprehensive and effective services within health sector budget 
constraints.
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OBJECTIVES: Chronic diseases account for 50% of the burden of disease (BoD) in 
Argentina, and cardiovascular diseases (CVD) represent 30% of deaths and 13% of 
YLL. The aim of this study was to develop a model to estimate the burden of CVD 
attributable to risk factors (RF), costs, and cost-effectiveness (CE) of different interven-
tions to reduce CVD METHODS: Selected CVRF(high blood pressure (HBP), high 
cholesterol, high glycemia, overweight, smoking, sedentary style, and unhealthy diet), 
were taken from each of the 50,000 individuals included in the Argentine Risk Factor 
Survey database, and entered into a simulation model with their relative risks for 
coronary heart disease and stroke. Six individual interventions (treatment of HBP, 
hypercholesterolemia, smoking cessation and polypill-like therapy to 3 different risk 
groups) and two population interventions (reduction of salt in bread and media cam-
paign against tobacco) were selected. Estimates of effectiveness of the interventions 
were used to predict their impact in DALY’s saved. Costs of acute CHD and stroke 
events were measured in Argentine pesos. ICERs were discounted at an annual rate 
of 3%. Probabilistic sensitivity analysis and acceptability curves were used as needed 
RESULTS: More than 80% of the events were attributable to these selected CVRF. 
Two interventions were cost-saving: reducing salt in bread and polypill treatment to 
high CV risk subjects, the latter with a reduction of 5% of BoD. Two interventions 
had acceptable ICER: HBP treatment ($4509/DALY saved) and anti-tobacco cam-
paign ($4939/DALY saved). Cholesterol lowering with atorvastatin ($61,000/DALY 
saved) and tobacco-cessation with bupropion ($92,000/DALY saved), showed less 
favorable ICER. CONCLUSIONS: Most of these interventions seem to be feasible and 
cost-effective. Taking into account that CVD is the leading cause of BoD in Argentina, 
interventions to reduce it should be prioritized. This model aims to help policy makers 
to make informed resource-allocation decisions to reduce CVD in Argentina.
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OBJECTIVOS: Realizar un analisis de costo efectividad de INFB1b frente a INFB1a 
en el tratamiento de pacientes con Esclerosis Multiple (EM) remitente recidivante en 
Colombia. METODOLOGÍAS: Se utilizo un modelo de Markov para simular una 
cohorte de pacientes de ambos generos recien diagnosticados de EM remitente recidi-
vante analizados por fases de progresion de la enfermedad (EDSS) y la presentacion 
de recaidas. Se usaron las probabilidades de transicion, tasas de desercion y utilidades 
usadas por Prosser (2004). Los costos se analizaron desde la perspectiva del tercero 
pagador y corresponden a la informacion presentada en un estudio de costos para 
Colombia en el 2008. Se analizaron tres desenlaces: muertes, recaidas evitadas y 
QALY. RESULTADOS: El costo no descontado de tratar una mujer en el brazo con 
INFB1a,fue de $394,356,043 (U$ 200,475) frente a $350,546,892 (U$178,204) en el 
brazo tratado con INFB1b, para un hombre fue de $363,693,465 (U$184,887) y 
$326,755,523 (U$ 166,109) respectivamente. Las recaidas con INFB1a para un 
hombre fueron de 16.84 y 15.96 en INFB1b, en una mujer 19.66 y 18.72 respectiva-
mente. Al aplicar las tasas de descuento, el brazo tratado con INFB1b es menos costoso 
y mas efectivo frente al tratado con INFB1a, siendo dominante para las recaidas evi-
tadas tanto en hombres como en mujeres. Se hizo analisis de sensibilidad que presenta 
resultados similares. Las utilidades y muertes no presentaron diferencias importantes 
entre los dos medicamentos. CONCLUSIONES: En Colombia es recomendable el uso 
de INFB1b frente a INFB1a en pacientes con EM RR dados los supuestos del caso 
base teniendo en cuenta los desenlaces analizados.
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OBJECTIVES: Prevalence of major depressive disorder (MDD) in Mexico has been 
estimated from 7% to 12%. Depression can be treated in a variety of ways, particu-
larly with medication and counseling. Selective serotonin reuptake inhibitors (SSRIs) 
appear to be the most widespread used antidepressants; besides, SSRIs are similar in 
efﬁcacy to the older tricyclic antidepressants (TCAs), but with fewer side effects. The 
objective of this analysis is to assess the cost-effectiveness of SSRIs in the treatment 
of major depressive disorder in Mexico from the health care payer’s perspective. 
METHODS: A cost-effectiveness analysis was developed using a decision-tree model 
that simulates costs and effectiveness outcomes in a 12- month period. The effective-
ness measure was the percentage of patients who experience remission from the 
depressive disorder. The comparators were citalopram 20 mg, ﬂouxetine 20 mg, esci-     
talopram 10 mg, paroxetine 20 mg, and sertraline 20 mg. Resource use and cost data              
were obtained from a panel of experts and ofﬁcial institutional databases from the 
Mexican Social Security Institute (IMSS). Effectiveness data and model transition 
probabilities were obtained from international published literature. Sensitivity analy-
ses were performed to determine the results robustness. RESULTS: The estimated 
effectiveness rate was 64.9% for citalopram and ﬂuoxetine compared to 79.6% for 
escitalopram, paroxetine, and sertraline. Average expected total direct costs per patient 
were lower for sertraline $2735.15 versus $2862.56 paroxetine, $3221.18 escitalo-
pram, $3804.36 ﬂuoxetine and $4110.70 citalopram. CONCLUSIONS: Sertaline is 
the most cost-effective selective serotonin reuptake inhibitor, among the comparators, 
for the treatment of major depression in Mexico from the health care payer’s 
perspective.
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OBJECTIVOS: Estimar la carga de enfermedad por hepatitis A en Colombia en el 
2007, y modelar el impacto epidemiológico y económico de la introducción de la 
vacuna de hepatitis A. METODOLOGÍAS: Estimación epidemiológica basada en una 
